Avandia, rosiglitazone generic, was approved in 1999 by the FDA (Food and Drug Administration) to treat 2 types of diabetes. It is estimated that around six million people use drugs worldwide to treat 2 types of diabetes.
An article published in the New England Journal of Medicine at the end of May 2007 stated that taking Avandia significantly increased the risk of a heart attack in diabetic patients. If you want to know more about diabetes drug attorneys then you can explore various online sources.
Responding to the article, the FDA issued a public security warning advising people who use Avandia to consult their doctors about cardiovascular risks associated with drug use.
After analyzing dozens of trials, it can be concluded that Avandia increases the risk of heart attack by 43% and heart-related deaths by 64%.
GlaxoSmithKline, a maker of Avandia, issued a news release for self-defense and drugs. Glaxo challenges the data presented in the New England Journal of Medicine study which states that it is too quick to draw the conclusion that Avandia increases the risk of cardiovascular problems in type 2 diabetes patients.
However, in 2000, Dr. John B. Buse, Head of Endocrinology at the University of North Carolina at Chapel Hill, wrote a letter to the FDA warning that Avandia showed "an alarming trend in cardiovascular death and severe side effects" among patients taking medication.
In July 2001, the FDA sent a Glaxo letter stating that the company's sales representative had minimized drug safety issues; The FDA asked Glaxo to send a letter to doctors prescribing Avandia warning them about the serious risks involved with taking the drug.